Intestinal fatty acid binding protein (I-FABP) is a protein released into the blood when the cells lining the small intestine are damaged. It serves as an early marker of intestinal mucosal injury.
I-FABP is often considered in the context of tiredness, reduced capacity, brain fog, or chronic exhaustion. This short overview clarifies what the marker can contribute, where its limits are, and when symptom or illness context becomes more important.
I-FABP is commonly relevant when fatigue raises questions about iron status, storage depletion, or anemia-related complaints. It can provide an important clue, but it rarely explains the full symptom picture by itself.
I-FABP does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
Intestinal Fatty Acid Binding Protein (I-FABP) is a small protein found almost exclusively in the enterocytes lining the small intestine. When these cells are injured, I-FABP is rapidly released into the bloodstream, where it can be measured as a biomarker for gut mucosal damage. Its measurement is useful in conditions where intestinal integrity is a concern, such as mesenteric ischemia, necrotizing enterocolitis, or inflammatory bowel disease. Because I-FABP rises quickly after injury, it may provide an early signal of intestinal distress before other clinical signs appear.
A low I-FABP level (within the laboratory reference range, typically less than 160 picograms per milliliter (pg/mL) or 160 nanograms per liter (ng/L), though lab-dependent) generally indicates that there is no significant acute damage to the small intestinal mucosa at the time of testing. However, a normal result does not exclude chronic, low-grade, or focal injury that may not cause a marked systemic elevation.
An elevated I-FABP level (above the lab’s reference range, e.g., greater than 160 pg/mL or 160 ng/L) may indicate injury to the lining of the small intestine. This can occur in conditions that reduce intestinal blood flow, such as mesenteric ischemia, or in inflammatory or necrotic processes like necrotizing enterocolitis.
Elevated I-FABP is not specific to one disease and can also be seen after abdominal trauma or surgery. Because I-FABP is cleared by the kidneys, impaired renal function can also raise levels.
This result is not specific for ME/CFS or Long COVID. Read it together with the clinical question, symptoms, related findings and the laboratory reference range rather than in isolation.
Practical details are separated from the general FAQ so they are easier to find.
I-FABP is commonly relevant when fatigue raises questions about iron status, storage depletion, or anemia-related complaints. It can provide an important clue, but it rarely explains the full symptom picture by itself.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
You now know which questions can matter when reading this result. With Elara you can keep the value and its surrounding context together over time.
Save the lab value with its date so individual measurements do not get lost.
See previous measurements together instead of relying on a single snapshot.
View Intestinal Fatty Acid Binding Protein (I-FABP) alongside symptom, energy, sleep and PEM entries without assuming one caused the other.
Export your history as a PDF — structured for the next check-up.
Normal I-FABP levels are typically below 160 picograms per milliliter (pg/mL), equivalent to 160 nanograms per liter (ng/L). However, reference ranges vary by laboratory and testing method. Values within the normal range suggest no significant acute intestinal mucosal damage.
A high I-FABP level suggests injury to the cells lining the small intestine. It can be elevated in conditions that compromise blood flow to the gut, such as mesenteric ischemia, or in inflammatory conditions like necrotizing enterocolitis. Because I-FABP rises quickly after damage, it is used as an early marker.
Yes, I-FABP is cleared by the kidneys, so reduced kidney function can lead to higher blood levels even without intestinal injury. Additionally, exercise, certain medications, or recent abdominal surgery may temporarily increase I-FABP. Always interpret results in the context of other clinical findings.
I-FABP does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
For many fatigue-related, inflammatory, hormonal, or recovery-linked markers, interpretation becomes stronger when symptoms, exertion response, and daily function are considered together.
I-FABP is rarely meaningful in isolation when fatigue, brain fog, or unstable capacity are central. The fatigue hub provides the broader lab-and-symptom context.
If symptoms worsen after activity with a delay, PEM often explains more than an isolated lab value alone.
Questionnaires help connect biomarkers to symptom patterns, functional limits, and patient-reported change over time.
Markers from the same system can add useful context when a single lab value is hard to interpret on its own.
No individual medical review is documented.
This English content was created with AI assistance and automatically validated. This is not an individual medical review.
These references support the information presented on this page.
https://www.imd-potsdam.de/fachinformationen/diagnostikinformationen/i-fabp-ein-biomarker-fuer-eine-gestoerte-darmbarrierefunktion
imd-potsdam.de
https://www.imd-berlin.de/fachinformationen/diagnostikinformationen/i-fabp-und-zonulin-zwei-serummarker-zum-nachweis-einer-gestoerten-darmbarrierefunktion
imd-berlin.de
https://www.inflammatio.de/faq/nahrungsmittelunvertraeglichkeit-leaky-gut
inflammatio.de
https://mibiota.de/blog/so-testest-du-auf-leaky-gut/
mibiota.de
https://www.lab4more.de/wp-content/uploads/2021/11/15_FA_OME_Entzu%CC%88ndung_Darm_ANE.pdf
lab4more.de
https://pmc.ncbi.nlm.nih.gov/articles/PMC9369469/
pmc.ncbi.nlm.nih.gov
https://www.imd-berlin.de/fileadmin/user_upload/Diag_Info/322_I-FABP_und_Zonulin-Serummarker_zum_Nachweis_einer_gestoerten_Darmbarrierefunktion.pdf
imd-berlin.de
https://noah.nrw/ulbmshsnoah/download/pdf/4292893
noah.nrw
https://pubmed.ncbi.nlm.nih.gov/31418255/
pubmed.ncbi.nlm.nih.gov
https://pubmed.ncbi.nlm.nih.gov/42645732/
pubmed.ncbi.nlm.nih.gov
This information does not replace medical advice. Lab values should be assessed in the context of your medical history, the reason for testing and other findings. Elara provides health information for orientation — not diagnoses or treatment decisions.
Bring your lab values, symptoms and energy into one shared context — so you walk into your next appointment more informed and structured.
